SCHEMBL17847415

SCHEMBL17847415

NC(C(=O)O)c1cc(Br)ccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.44
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 1/20 0.41
GRM1 Q13255 6/20 0.40
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 2/20 0.38
GLA P06280 1/20 0.38
APLNR P35414 2/20 0.37
LMNA P02545 3/20 0.36
NPC1 O15118 2/20 0.36
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25907635 0.81 CES2 (0.50) KMT2AMEN1CYP1A2CYP3A4GRM1
SCHEMBL17847411 0.80 ALDH1A1 (0.40) DGAT1KMT2AMEN1TDP1KDM4E
SCHEMBL6818451 0.80 CES2 (0.45) DGAT1KMT2AKDM4EGLALMNA
SCHEMBL9004079 0.80 MEN1 (0.64) KMT2AMEN1CYP1A2CYP3A4GRM1
SCHEMBL9004077 0.80 MEN1 (0.64) KMT2AMEN1CYP1A2CYP3A4GRM1
SCHEMBL3848904 0.79 DGAT1 (0.41) DGAT1KMT2AMEN1KDM4EGLA
SCHEMBL11516331 0.78 GRM1 (0.46) KMT2AMEN1CYP1A2CYP3A4GRM1
SCHEMBL17865282 0.78 ALOX5 (0.40) DGAT1KMT2AMEN1CYP1A2CYP3A4
SCHEMBL4930943 0.77 AAK1 (0.40) DGAT1APLNR
SCHEMBL20256754 0.77 DPP4 (0.40) DGAT1KMT2AMEN1KDM4EAPLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338262-B2 Modulators of TNF-alpha activity FORWARD THERAPEUTICS, INC. (US) 2025-06-24 US disclosed
US-20240279258-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. 2024-08-22 US disclosed
US-11987597-B2 Modulators of TNF-α activity FORWARD THERAPEUTICS, INC. (US) 2024-05-21 US disclosed
US-20240076306-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. 2024-03-07 US disclosed
WO-2023240253-A2 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023240253-A2 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
EP-3233834-B1 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE JANSSEN PHARMACEUTICA NV (BE) 2019-11-13 EP disclosed
US-10106524-B2 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase JANSSEN PHARMACEUTICA NV (BE) 2018-10-23 US disclosed
US-20170362198-A1 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE COMPOUND INHIBITORS OF BETA-SECRETASE JANSSEN PHARMACEUTICA NV (BE) 2017-12-21 US disclosed
EP-3233834-A1 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE COMPOUND INHIBITORS OF BETA-SECRETASE Janssen Pharmaceutica, N.V. (BE) 2017-10-25 EP disclosed
WO-2016096979-A1 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE COMPOUND INHIBITORS OF BETA-SECRETASE JANSSEN PHARMACEUTICA NV (BE) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362198-A1 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE COMPOUND INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APP DGAT1 1576/4885KMT2A 3696/4885MEN1 1768/4885
US-20240279258-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, NFKBIA DGAT1 1854/4885KMT2A 4765/4885MEN1 4664/4885
US-11987597-B2 Modulators of TNF-α activity TNF, TNFRSF1A, NFKBIA DGAT1 1640/4885KMT2A 4733/4885MEN1 4727/4885
US-10106524-B2 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase BACE1, BACE2, APP DGAT1 1576/4885KMT2A 3696/4885MEN1 1768/4885
US-20240076306-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, NFKBIA DGAT1 1854/4885KMT2A 4765/4885MEN1 4664/4885
US-12338262-B2 Modulators of TNF-alpha activity TNF, TNFRSF1A, NFKBIA DGAT1 1854/4885KMT2A 4765/4885MEN1 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.